Celgene partners on Phase 0 cancer drug studies; FDA lifts clinical hold on Xencor's bispecific
→ Celgene is tying up with Seattle-based Presage Biosciences to test its early-stage cancer drugs on patients in Phase 0 studies. In Phase 0, patients are given microdoses of a drug to test patient responses. It’s one way to help increase the odds of success, and help overcome the inherent limitations of animal studies.
→ Tmunity and the University of California San Francisco will enter a licensing and research collaboration to advance TCR therapies for currently incurable pediatric cancers with high mortality rates. The company says that initial research will focus on diffuse intrinsic pontine glioma (DIPG), a rare and highly aggressive brain stem tumor, which affects around 300 children in the US each year. Hideho Okada, a professor of neurological surgery at UCSF who devised the TCR at the center of the pact, will work with Tmunity through IND-enabling studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
